Free Trial
NYSE:NVRO

Nevro Q4 2024 Earnings Report

Nevro logo
$5.85 +0.01 (+0.10%)
Closing price 04/2/2025
Extended Trading
$5.85 0.00 (0.00%)
As of 04/2/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Nevro EPS Results

Actual EPS
-$0.64
Consensus EPS
-$0.79
Beat/Miss
Beat by +$0.15
One Year Ago EPS
N/A

Nevro Revenue Results

Actual Revenue
$105.55 million
Expected Revenue
$102.61 million
Beat/Miss
Beat by +$2.94 million
YoY Revenue Growth
N/A

Nevro Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Tuesday, March 4, 2025
Conference Call Time
4:00PM ET

Upcoming Earnings

Nevro's next earnings date is estimated for Tuesday, May 6, 2025, based on past reporting schedules.

Remove Ads

Nevro Earnings Headlines

Trump Treasure April 19
Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly that, just 12 months later…
See More Nevro Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Nevro? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nevro and other key companies, straight to your email.

About Nevro

Nevro (NYSE:NVRO), a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems. It also offers Senza HFX iQ platform, that includes HFX iQ implantable pulse generator, HFX trial stimulator, and HFX iQ patient remote, as well as HFX App, a patient remote control and the wireless trialing system; and provides sacroiliac joint fusion devices under NevroV1, NevroFix, and NevroPro brands. In addition, the company offers surpass surgical and percutaneous leads. It sells its products through its direct sales force, and a network of sales agents and independent distributors. The company was incorporated in 2006 and is headquartered in Redwood City, California.

View Nevro Profile

More Earnings Resources from MarketBeat